REDX.L Share News (REDX)

UK earnings, trading statements calendar - next 7 days

TRADING UPDATES: De La Rue defends chair; Resolute Mining fundraise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

TRADING UPDATES: Scirocco repays loan; Vp says rail strikes slow works

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

TRADING UPDATES: Blencowe Resources sees potential interest from China

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Redx Pharma staff sell 1.5 million shares via accelerated bookbuild

(Alliance News) - Redx Pharma PLC on Friday confirmed that Chief Scientific Officer Richard Armer and other current and former employees have sold a total of 1.5 million shares at 59 pence each via an accelerated bookbuild.

IN BRIEF: Redx Pharma employees to sell at least GBP605,120 in shares

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Chief Scientific Officer Richard Armer and other current and former employees look to sell 1.5 million shares at a minimum price of 59 pence each via an accelerated bookbuild, which is 11% discount to Tuesday's closing price of 66.50p.

IN BRIEF: Redx Pharma reports "encouraging" fibrosis treatment data

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Notes encouraging preclinical data for the potential of its Porcupine and ROCK inhibitors to tackle cancer-associated fibrosis. Further data supported the ROCK inhibitor as a potential treatment for fibrostenotic Crohn's disease.

IN BRIEF: Redx Pharma narrows half-year loss as pipeline progresses

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - In the half year ended March 31, pretax loss narrows to GBP9.7 million from GBP12.7 million year-on-year. Revenue multiplies to GBP8.4 million from GBP2.1million. Reports strong progress across its pipeline, especially its lead oncology asset RXC004 moving into phase II clinical trials, and its lead fibrosis asset, RXC007, reporting "encouraging" phase I safety data. Says its Rock inhibitor RXC008 has the potential to become a first-in-class treatment for fibrostenotic Crohn's disease, and is likely to be ready to enter the clinic by the end of next year.

UK earnings, trading statements calendar - next 7 days

Redx Pharma rises on FDA clearance for solid tumour treatment JZP815

(Alliance News) - Redx Pharma PLC on Wednesday said the US Food & Drug Administration has cleared the investigational new drug application for JZP815, a pan-RAF inhibitor for the treatment of solid tumours and haematological malignancies.

TRADING UPDATES: Knights tips revenue hike; Gym Group eyes growth

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

IN BRIEF: Redx Pharma to raise GBP30 million to fund pipelines

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Proposes to raise GBP30 million through a placing to institutional investors of shares at a price of 59 pence each.

IN BRIEF: Redx Pharma notes "encouraging" RXC004 data in cancer

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Notes "encouraging" preclincal data for RXC004 as a targeted therapy for Wnt-ligand driven cancer.

TRADING UPDATES: Alpha FX restarts relationship; Atalaya resources up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

IN BRIEF: Redx Pharma to start new Crohn's disease study in late 2023

Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - Announces end of 2023 as start of phase 1 studies for its Crohn's disease clinical development candidate RXC008. The inhibitor is designed to act exclusively in the gastrointestinal tract at the site of fibrosis in Crohn's disease patients. Up to 50% of patients with Crohn's disease can develop significant fibrosis, the company says, citing a 2013 study published by the National Center for Biotechnology Information based in Bethesda, Maryland, United States.